Table 3. Cox proportional hazard model for the whole cohort.
| Clinical characteristics | Overall survival | Prostate cancer-specific survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age at the time of diagnosis, year | 1.016 | 0.98-1.053 | 0.401 | 0.999 | 0.951-1.05 | 0.976 |
| Year of diagnosis | 1.114 | 1.01-1.228 | 0.030 | 1.06 | 0.927-1.211 | 0.395 |
| PSA, ng/mL | 0.996 | 0.984-1.008 | 0.530 | 1.003 | 0.989-1.016 | 0.702 |
| T staging | 1.897 | 1.179-3.054 | 0.008 | 1.87 | 1.018-3.436 | 0.044 |
| N staging | 0.255 | 0.029-2.238 | 0.218 | 0.767 | 0.083-7.062 | 0.815 |
| M staging | 0.686 | 0.231-2.037 | 0.497 | 0.396 | 0.087-1.802 | 0.231 |
| Gleason score | 0.966 | 0.862-1.082 | 0.546 | 0.924 | 0.796-1.072 | 0.295 |
| Management approach | 0.509 | 0.173-1.501 | 0.221 | 1.096 | 0.296-4.064 | 0.891 |
95% CI, 95% confidence interval; HR, hazard ratio.